Reporting Period 2010-2011
From choice, a world of possibilities
Want to change the world? Here's how...
"i asked: 'Why doesn't somebody do something?' Then I realized I was somebody"
Getting to Zero
Sustainable Financing of National HIV Responses
The Consensus Statement on c-IPTp is a publication by the RBM Partnership to End Malaria. It focuses on community-based intermittent preventive treatment in pregnancy (c-IPTp), aiming to enhance malaria prevention among pregnant women through community-level interventions. The statement offers po...licies, recommendations, and joint statements to guide the implementation of c-IPTp strategies. The document is available for download in English, French, and Portuguese.
more
Ce plan intégré de lutte contre les MNT au Burkina Faso tient compte dans une large mesure des résultats de cette enquête et des cibles principales du nouveau plan mondial de lutte contre les MNT 2013-20201
. S’inscrivant dans la logique du PNDS, il s’est voulu multisectoriel et intègre tr...ois principaux piliers de la stratégie mondiale de
lutte contre les maladies non transmissibles 2013-2020, à savoir la surveillance, la
prévention et la prestation de soins de santé dans le cadre de systèmes de santé.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Report of Meeting: 4 November 2014, Roma
Global UNIDO Project: Strengthening the local production of essential generic drugs in the least developed and developing countries
In response to a call by the United Nations Secretary-General and the Governments of Guinea, Liberia and Sierra Leone, an international team conducted an Ebola Recovery Assessment.The aim was to contribute towards laying the foundation for short-, medium- and long-term recovery while the medical eme...rgency response continues to tackle the epidemic.
This summary report is based on a full report as well as three detailed reports submitted to each of the three governments as contributions to their national recovery planning processes.
more
Background
Cardiovascular diseases (CVDs) are one of the global leading causes of concern due to the rising prevalence and consequence of mortality and disability with a heavy economic burden. The objective of the current study was to analyze the trend in CVD incidence, mortality, and mortality-to-...incidence ratio (MIR) across the world over 28 years.
Methods
The age-standardized CVD mortality and incidence rates were retrieved from the Global Burden of Disease (GBD) Study 2017 for both genders and different world super regions with available data every year during the period 1990–2017. Additionally, the Human Development Index was sourced from the United Nations Development Programme (UNDP) database for all countries at the same time interval. The marginal modeling approach was implemented to evaluate the mean trend of CVD incidence, mortality, and MIR for 195 countries and separately for developing and developed countries and also clarify the relationship between the indices and Human Development Index (HDI) from 1990 to 2017.
Results
The obtained estimates identified that the global mean trend of CVD incidence had an ascending trend until 1996 followed by a descending trend after this year. Nearly all of the countries experienced a significant declining mortality trend from 1990 to 2017. Likewise, the global mean MIR rate had a significant trivial decrement trend with a gentle slope of 0.004 over the time interval. As such, the reduction in incidence and mortality rates for developed countries was significantly faster than developing counterparts in the period 1990–2017 (p < 0.05). Nevertheless, the developing nations had a more rather shallow decrease in MIR compared to developed ones.
Conclusions
Generally, the findings of this study revealed that there was an overall downward trend in CVD incidence and mortality rates, while the survival rate of CVD patients was rather stable. These results send a satisfactory message that global effort for controlling the CVD burden was quite successful. Nonetheless, there is an urgent need for more efforts to improve the survival rate of patients and lower the burden of this disease in some areas with an increasing trend of either incidence or mortality.
more
Lancet Oncol 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S1470-2045(18)30447-9